FindTrial
Sign In

Using exposure-response models to predict the risk of tigecycline-related coagulation adverse reactions: a retrospective study based on medical records from 2019 to 2021

Using exposure-response models to predict the risk of tigecycline-related coagulation adverse reactions: a retrospective study based on medical records from 2019 to 2021

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053866
Enrollment
Unknown
Registered
2021-12-01
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious Disease

Interventions

coagulation group vs. non coagulation group:Nil

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Inpatients treated with tigecycline in our hospital from January 2019 to September 2021; 2. Aged > 18 years; 3. Medication > 3 days; 4. Monitor blood drug concentration at least once during treatment; 5. At least one coagulation function monitoring before, during and after treatment.

Exclusion criteria

Exclusion criteria: 1. Loss of clinical data; 2. Fibrinogen < 2g/L before administration; 3. Pregnant or lactating patients.

Design outcomes

Secondary

MeasureTime frame
Adverse coagulation reaction;—

Primary

MeasureTime frame
Blood concentration of tigecycline;—

Countries

China

Contacts

Public ContactJin Lu

Nanjing Drum Tower Hospital

Kingbar47@163.com+86 13611571156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026